Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Identification of chemokines and cytokines offers new hope for inflammatory myopathy patients

10.09.2002


The inflammatory myopathies comprise three different entities: polymyositis, inclusion body myositis and dermatomyositis. People in all age groups can be affected by major muscle weakness and pain, and show evidence of muscle fiber breakdown in the serum. Autoimmune pathogenetic mechanisms have been identified in each inflammatory myopathy, but the antigen(s) recognized by the autoreactive inflammatory cells and the factors eliciting the aberrant immune responses remain unknown. Currently, patients are treated with corticosteroids with variable success rates and at a high cost of side-effects.



The ongoing research is aimed at identifying the factors that guide the trafficking of inflammatory cells from the blood to the inflamed muscle tissue. A new study reports the differential expression of chemokines and their receptors in each inflammatory myopathy. Chemokines represent a family of small-molecular weight cytokines that have an important role in the migration of distinct leukocyte subsets to the sites of inflammation. The chemokines monocyte chemoattractant protein-1 (MCP-1) and stromal derived factor (SDF-1a and SDF-1b) and their receptors are strongly expressed whereas a number of others are undetectable.

Blocking the autoimmune cascade by targeting chemokines or chemokine receptors has given excellent results in animal models of other immune diseases. The present work identifies the candidates for selective immune intervention in patients suffering autoimmune inflammatory myopathies and may well lead to more selective treatment modalities with less side-effects than the currently available drugs.


Previous research by this group had focused on other factors that control recruitment and activation of immune cells, such as cell adhesion molecules and cytokines. Based in part on data that described the role of the cytokine tumor necrosis factor-a (TNF-a) and its receptors in inflammatory myopathy muscle biopsies, preliminary clinical studies with TNF-blocking monoclonal antibodies are now being initiated in several hospitals. "It is very encouraging to see data obtained from clinically oriented research move from the laboratory bench to the clinical treatment phase in just a few years time", said Professor Jan De Bleecker who is the first author of these papers.

Jan DE BLEECKER | alfa

More articles from Health and Medicine:

nachricht World first: Massive thrombosis removed during early pregnancy
20.07.2017 | Universitätsspital Bern

nachricht Therapy of preterm birth in sight?
19.07.2017 | Universitätsspital Bern

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Manipulating Electron Spins Without Loss of Information

Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.

For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...

Im Focus: The proton precisely weighted

What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.

To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...

Im Focus: On the way to a biological alternative

A bacterial enzyme enables reactions that open up alternatives to key industrial chemical processes

The research team of Prof. Dr. Oliver Einsle at the University of Freiburg's Institute of Biochemistry has long been exploring the functioning of nitrogenase....

Im Focus: The 1 trillion tonne iceberg

Larsen C Ice Shelf rift finally breaks through

A one trillion tonne iceberg - one of the biggest ever recorded -- has calved away from the Larsen C Ice Shelf in Antarctica, after a rift in the ice,...

Im Focus: Laser-cooled ions contribute to better understanding of friction

Physics supports biology: Researchers from PTB have developed a model system to investigate friction phenomena with atomic precision

Friction: what you want from car brakes, otherwise rather a nuisance. In any case, it is useful to know as precisely as possible how friction phenomena arise –...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Closing the Sustainability Circle: Protection of Food with Biobased Materials

21.07.2017 | Event News

»We are bringing Additive Manufacturing to SMEs«

19.07.2017 | Event News

The technology with a feel for feelings

12.07.2017 | Event News

 
Latest News

NASA looks to solar eclipse to help understand Earth's energy system

21.07.2017 | Earth Sciences

Stanford researchers develop a new type of soft, growing robot

21.07.2017 | Power and Electrical Engineering

Vortex photons from electrons in circular motion

21.07.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>